Andere talen Veracyte, Inc.

Aandelen

VCYT

US92337F1075

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 17-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
18,86 ^USD	-0,32%		-8,93%	-31,44%

15/04	VERACYTE, INC. : Goldman Sachs nog altijd een koopadvies	ZM
26/02	VERACYTE, INC. : Morgan Stanley geeft een verkoopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024	16/04
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines	27/02
Sector Update: Health Care Stocks Mixed Premarket Friday	23/02
Veracyte's Q4 Loss Widens, Revenue Increases; Issues 2024 Revenue Outlook; Shares Down Pre-Bell	23/02
Veracyte: Q4 Earnings Snapshot	22/02
Earnings Flash (VCYT) VERACYTE Reports Q4 Revenue $98.2M, vs. Street Est of $92.8M	22/02
Veracyte, Inc. Provides Earnings Guidance for the Full Year 2024	22/02
Veracyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/02
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results	22/02
Veracyte, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference	21/02
Veracyte, Inc. Announces Retirement of John L. Bishop, A Member of the Board of Directors	13/02
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024	08/02
Veracyte Closes $70 Million C2i Genomics Acquisition	06/02
Veracyte Completes Acquisition of C2i Genomics	06/02
Veracyte, Inc. completed the acquisition of C2i Genomics, Inc.	05/02
Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform	08/01
Veracyte, Inc. Provides Preliminary Unaudited Earnings Results for Fourth Quarter and Full Year Ended December 31, 2023	08/01
Veracyte, Inc. has reached a definitive agreement to acquire C2i Genomics, Inc. for $95 million.	08/01
Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference	12/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Veracyte, Inc.

Aandelen

VCYT

US92337F1075

Andere talen

Filters